Phase 3 Lung Cancer Trial, Recruiting NCT06980272 Sponsor: Shenyang Sunshine Pharmaceutical Co., LTD. Condition: Lung Cancer
Back to Lung Cancer

Phase 3 Lung Cancer Trial, Recruiting

NCT06980272
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to take part voluntarily, follow all study procedures, and sign a consent form.
  • People who are 18 years of age or older at the time of signing the consent form, of any gender.
  • People whose general health and ability to carry out daily activities meets a specific scoring level (rated 0 or 1 on a standard scale used by doctors to measure how cancer affects daily functioning — confirm with trial site).
  • People with a life expectancy of at least 12 weeks.
  • People who have been confirmed through laboratory testing of tissue or cell samples to have a certain type of lung cancer (non-small cell lung cancer) that is either locally advanced (Stage IIIB or IIIC) or has spread to other parts of the body (Stage IV).
  • People who have not previously received any systemic drug treatment for locally advanced or metastatic non-small cell lung cancer.
  • People who have at least one tumour that can be measured using standard imaging criteria (confirm with trial site).

Who may not be able to join:

  • People whose lung cancer tissue samples contain a type of cancer cell called small cell carcinoma.
  • People whose lung cancer has specific genetic changes known as EGFR-sensitive mutations or ALK fusion.
  • People whose lung cancer has certain other specific genetic changes, including BRAF V600E, MET exon 14 skipping, NTRK fusion, RET fusion, or ROS1 fusion (confirm with trial site).
  • People who have cancer that has spread to the brainstem, the lining of the brain and spinal cord, the spinal cord itself, or is pressing on the spinal cord.
  • People who still have side effects from a previous cancer treatment that have not settled back to a mild or absent level (as defined by a standard medical grading scale — confirm with trial site).
  • People who have previously had an organ transplant or a bone marrow/stem cell transplant from another person.
  • People who have a history of immune system deficiency, or who test positive for HIV.
  • People with a currently active tuberculosis (TB) infection.
  • People with a known history of severe allergic reactions to any ingredient in the study drug, or to similar types of antibody-based treatments.
  • People who are pregnant or currently breastfeeding.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 7 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Phone: 13301825532

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Shenyang Sunshine Pharmaceutical Co., LTD.
Registry
ClinicalTrials.gov
Start date
20 June 2025
Est. completion
30 July 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

PFS assessed by IRRC per RECIST v1.1

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov